Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Licenses Genes For Hereditary Hemochromatosis From Bio-Rad

NEW YORK, June 25-Bio-Rad has granted Nanogen a license to two mutations associated with hereditary hemochromatosis for use with the company's NanoChip microarray system, the two companies said today.


The license is worldwide and nonexclusive. The companies did not disclose financial details of the agreement.


By the end of the year, Nanogen plans to introduce a three-SNP test for the simultaneous detection of the three most common mutations associated with this disease.


Hereditary hemochromatosis, or iron overload disease, is the most common inherited single-gene disorder among people of northern European descent. In the disease, increased intestinal iron absorption can ultimately lead to diabetes, liver cirrhosis, cardiomyopathy, impotence, and ultimately death.


About one in 10 white people carries one of the HH mutations, and approximately one in 250 to 300 is homozygous for the mutation, but the disorder is rarely diagnosed. Early diagnosis and regular treatment, including phlebotomy, can provide patients with a normal life expectancy.


Bio-Rad is a multinational lab supply and diagnostics company based in Hercules, Calif.


Nanogen, based in San Diego, Calif., is developing its gene chip system for use in clinical diagnostics.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in  dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.